• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MIBEFRADIL Drug Record

  • Summary
  • Interactions
  • Claims
  • MIBEFRADIL chembl:CHEMBL45816

    Alternate Names:

    POSICOR
    MIBEFRADIL
    POSICOR 100
    POSICOR 50
    POSICOR®
    RO-405967-001
    chemidplus:116644-53-2
    drugbank:01388
    pubchem.compound:60663
    rxcui:83213
    chembl:CHEMBL45816

    Drug Info:

    (0 More Sources)

    Publications:

    Fitzgerald PT et al., 2005, Drug-induced torsades de pointes: the evolving role of pharmacogenetics., Heart Rhythm
    Lee et al., 2006, Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms., Pharmacology
    Clozel et al., 1997, Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker., J Hypertens Suppl
    Coste et al., 2007, Pharmacological dissection and distribution of NaN/Nav1.9, T-type Ca2+ currents, and mechanically activated cation currents in different populations of DRG neurons., J. Gen. Physiol.
    Brueggemann et al., 2005, Low voltage-activated calcium channels in vascular smooth muscle: T-type channels and AVP-stimulated calcium spiking., Am. J. Physiol. Heart Circ. Physiol.
    McNulty et al., 2004, State-dependent mibefradil block of Na+ channels., Mol. Pharmacol.
    Cribbs et al., 1998, Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family., Circ. Res.
    Perez-Reyes, 2004, Paradoxical role of T-type calcium channels in coronary smooth muscle., Mol. Interv.
    Massie, 1997, Mibefradil: a selective T-type calcium antagonist., Am. J. Cardiol.
    Foti RS et al., 2011, Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction., Drug Metab Dispos
  • MIBEFRADIL   CACNA1H

    Interaction Score: 2.29

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    16899990 9481612 17190903 15498818 15562257 9670923 14993472 9375939


    Sources:
    TTD

  • MIBEFRADIL   THPO

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MIBEFRADIL   MTOR

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MIBEFRADIL   MAPK1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MIBEFRADIL   KCNH2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16253929


    Sources:
    PharmGKB

  • MIBEFRADIL   ATXN2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MIBEFRADIL   ATAD5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MIBEFRADIL   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21447734


    Sources:
    DTC

  • MIBEFRADIL   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DTC: MIBEFRADIL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL45816 ChEMBL Drug ID

    Drug Info:

    Publications:
    Foti RS et al., 2011, Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction., Drug Metab Dispos

  • PharmGKB: mibefradil

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Fitzgerald PT et al., 2005, Drug-induced torsades de pointes: the evolving role of pharmacogenetics., Heart Rhythm

  • TTD: Mibefradil

    • Version: 2020.06.01

    Alternate Names:
    D0W8XT TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL45816

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21